Vasu Pharma Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 31-12-2024
- Paid Up Capital ₹ 9.51 Cr
as on 31-12-2024
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.00 Cr
as on 31-12-2024
About Vasu Pharma Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.51 Cr.
The company currently has active open charges totaling ₹18.00 Cr.
Akshay Bejgam, Gaurav Chaturvedi, and Ramesh Bejgam serve as directors at the Company.
- CIN/LLPIN
U51397TG2022PTC160705
- Company No.
160705
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2022
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vasu Pharma Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Bejgam  | Managing Director | 21-Mar-2022 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gaurav Chaturvedi | Director | 09-Jan-2024 | Current |
| Akshay Bejgam | Director | 21-Mar-2022 | Current |
Financial Performance of Vasu Pharma Drugs.
Vasu Pharma Drugs Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Vasu Pharma Drugs?
In 2023, Vasu Pharma Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vasu Organics Private LimitedActive 10 years 10 monthsAkshay Bejgam and Ramesh Bejgam are mutual person
Vasu Agencies Drugs Private LimitedActive 2 years 9 monthsGaurav Chaturvedi and Ramesh Bejgam are mutual person
- Lakshmi Annapurna Medical Distributors Private LimitedActive 3 years 5 months
Gaurav Chaturvedi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 May 2023 | ₹18.00 Cr | Open |
How Many Employees Work at Vasu Pharma Drugs?
Vasu Pharma Drugs has a workforce of 69 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vasu Pharma Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vasu Pharma Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
